Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Piper Sandler Downgrades Accenture to Underweight

Piper Sandler analyst Arvind Ramnani downgrades Accenture (NYSE:ACN) from Neutral to Underweight.
byBenzinga Newsdesk
December 12, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Piper Sandler analyst Arvind Ramnani downgrades Accenture (NYSE:ACN) from Neutral to Underweight.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases

By Vandana Singh
May 27, 9:43 AM
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD, Parkinson's, and Alzheimer's, emphasizing a transformative approach to immune balance restoration.

BBIB